HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The new nitroderivative ITF 296 improves collateral blood flow in a canine model of coronary thrombosis.

Abstract
The actions of ITF 296 and isosorbide dinitrate (ISDN), 20, 70, and 200 g/kg/min, on myocardial transmural blood flow distribution during acute thrombotic occlusion of the left circumflex coronary artery (LCX) have been evaluated in seven and three anesthetized open-chest dogs, respectively, and compared with four animals receiving vehicle. Occlusion of LCX was achieved in 14 +/- 2 min by the insertion of a copper coil. This caused transmural myocardial ischemia in the LCX area, while leaving blood flow in the left anterior descending coronary artery (control area) unaffected. Infusion of ITF 296 (200 g/kg/min) increased transmural coronary flow in the border zone and in the control area without affecting blood flow in the central ischemic area. ISDN, given in the same dose, reduced systemic blood pressure but did not affect LCX blood flow. In three dogs with residual perfusion in the LCX central area ITF 296 also increased blood flow. These results confirm that ITF 296 promotes an increase of flow to the border zone, thus possibly reducing the area of myocardial infarction.
AuthorsM G Trivella, G Barsotti, R Cereda, F Chiaverini, G Gromo, A L'Abbate, D Magnozzi, J Mizrahi, G Pelosi, L Taddei
JournalJournal of cardiovascular pharmacology (J Cardiovasc Pharmacol) Vol. 26 Suppl 4 Pg. S31-6 ( 1995) ISSN: 0160-2446 [Print] United States
PMID8839224 (Publication Type: Journal Article)
Chemical References
  • Benzoxazines
  • Nitrates
  • Oxazines
  • Vasodilator Agents
  • Isosorbide Dinitrate
  • sinitrodil
Topics
  • Anesthesia
  • Animals
  • Benzoxazines
  • Collateral Circulation (drug effects)
  • Coronary Circulation (drug effects)
  • Coronary Thrombosis (physiopathology)
  • Dogs
  • Female
  • Isosorbide Dinitrate (pharmacology)
  • Male
  • Microspheres
  • Nitrates (pharmacology)
  • Oxazines (pharmacology)
  • Vasodilator Agents (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: